|
Field
Trial Start Date
|
Before
June 01, 2024
|
After
July 17, 2024
|
|
Field
Last Published
|
Before
May 29, 2024 01:02 PM
|
After
July 11, 2024 12:57 PM
|
|
Field
Intervention Start Date
|
Before
June 15, 2024
|
After
July 17, 2024
|
|
Field
Intervention End Date
|
Before
July 15, 2024
|
After
August 17, 2024
|
|
Field
Primary Outcomes (Explanation)
|
Before
1) PDMP Engagement: An indicator for increased PDMP engagement during the 2-month period after the first e-mails were sent. It will indicate whether the level of engagement rose from the baseline level that resulted in the clinician’s enrollment into the study. For clinicians who lacked an account, the outcome will indicate whether they created one; for clinicians with an inactive account, the outcome will indicate whether they reactivated it. For those who never searched, it will indicate any search, and for those who rarely searched, it will indicate whether their search rate rose.
2) Potentially Guideline-Discordant Opioid Prescribing: A composite of several measures of potentially guideline-discordant opioid prescribing. These will include:
1. Opioid co-prescriptions with other opioids
2. Opioid co-prescriptions with benzodiazepines, gabapentinoids, and stimulants
3. High daily opioid doses
4. Long-duration opioid prescriptions to opioid-naïve individuals
|
After
1) PDMP Engagement: An indicator for increased PDMP engagement during the 2-month period after the first e-mails were sent. It will indicate whether the level of engagement rose from the baseline level that resulted in the clinician’s enrollment into the study. For clinicians who lacked an account, the outcome will indicate whether they created one; for clinicians with an inactive account, the outcome will indicate whether they reactivated it. For those who never searched, it will indicate any search, and for those who rarely searched, it will indicate whether their search rate rose.
2) Potentially Guideline-Discordant Opioid Prescribing: A composite of several measures of potentially guideline-discordant opioid prescribing. These will include:
1. Opioid co-prescriptions with other opioids
2. Opioid co-prescriptions with benzodiazepines
3. Opioid co-prescriptions with gabapentinoids
4. High daily opioid doses
5. Long-duration opioid prescriptions to opioid-naïve individuals
|
|
Field
Randomization Method
|
Before
Randomization with optimal stratification to maximize statistical power on primary endpoints
|
After
Randomization with optimal stratification to maximize statistical power on primary prescribing endpoint
|
|
Field
Secondary Outcomes (End Points)
|
Before
Secondary outcomes include search query volume, creation of delegate users, characteristics of average patient searched by clinicians, e-mail engagement (open, click-through, and bounce), and volume measures of prescribing (e.g. days supplied of controlled substances, days supplied of opioids, and total opioid morphine milligram equivalents)
|
After
Secondary outcomes include search query volume, creation of delegate users, characteristics of average patient searched by clinicians, e-mail engagement (open, click-through, and bounce), and volume measures of prescribing (e.g. days supplied of controlled substances, days supplied of opioids, and total opioid morphine milligram equivalents). The full set of secondary outcomes will be specified in the pre-analysis plan.
|